Noticias corporativas
- Todo
- Eventos y Exposiciones
- Feeds de Redes Sociales
- Noticias corporativas
- Noticias de FarmaMondo
noviembre 29, 2024
GSASA CONGRESS
julio 15, 2024
Farma Mondo Hong Kong Ltd. and Recordati UK Ltd. sign exclusive license and distribution agreement for Qarziba® in Hong Kong
julio 4, 2024
FarmaMondo Group and HRA Pharma Rare Diseases Sign Exclusive Partnership to Distribute Lysodren (Mitotane) in Brazil
marzo 1, 2024
FarmaMondo Group and Stemline Therapeutics B.V. sign exclusive partnership to grant access to Elacestrant
junio 1, 2023
Dompé farmaceutici and FarmaMondo Group extend their Distribution Partnership for Oxervate®
julio 28, 2023
FarmaMondo Group signs exclusive partnership to commercialize QRX003 for Netherton Syndrome in Singapore
Chiasso, Switzerland and Ashburn, US – 28th July, 2023 – Farma Mondo Group, a Swiss-based pharmaceutical group focused on providing market access and speciality distribution services through a unique infrastructure and geographical footprint across emerging and emerged markets, announces today the signing of a licensing and distribution agreement with Quoin Pharmaceuticals Inc. for exclusive rights to commercialize QRX003 in Singapore.
febrero 6, 2023
Farma Mondo Group and KYAN Therapeutics sign exclusive partnership to commercialize OPTIM.AI in the MENA region
noviembre 28, 2022
Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region
noviembre 2, 2022
Recordati Rare Diseases and the FarmaMondo Group sign a new exclusive agreement for three RRD’s rare disease therapies in Hong Kong
julio 15, 2022
FarmaMondo receives Marketing Authorisation for Qarziba® (dinutuximab beta) for infants with High Risk Neuroblastoma
junio 7, 2022
Molteni SPA nominates the FarmaMondo Group as the exclusive partner for its pain and addiction portfolio in Egypt.
mayo 9, 2022
Amryt Pharma and the FarmaMondo Group sign a new exclusive agreement for two Amryt’s rare disease therapies in the APAC region.
abril 28, 2022
OUR STAFF
enero 15, 2022
FarmaMondo and Accendatech USA Inc. partnered to initiate a Managed Access Program for the compassionate supply of ACT-001 for patients in Hong Kong
septiembre 10, 2021
Mirum pharmaceuticals and FarmaMondo Group enter into an exclusive commercialization agreement for Russia and CIS region
julio 26, 2021
Ideogen AG and FarmaMondo enter into a managed access program agreement to allow Fotolyn, Beleodaq and Marqibo distribution in Russia, CIS market and Baltics
diciembre 27, 2020
Sarepta Therapeutics and FarmaMondo announce an agreement to exclusively manage access of eteplirsen and golodirsen in Russia
noviembre 10, 2020
Dompe’ farmaceutici and the FarmaMondo Group: exclusive agreement to distribute oxervate™ in Russia and other CIS countries
junio 1, 2020
FarmaMondo to exclusively manage access to Metreleptin (Myalept®) by Amryt Pharma for patients with lipodystrophy in CIS (excluding Russia)
abril 14, 2020
EUSA and FarmaMondo Group establishes an Emergency Managed Access Program to allow Healthcare Providers to access Siltuximab (Sylvant©) for off label treatment of acute patients of COVID-19
octubre 2, 2019
FarmaMondo to exclusively Manage Access to Lomitapide (Lojuxta®) for the Swiss and CIS markets
junio 1, 2019
FarmaMondo to exclusively manage access of Qarziba® (Dinutuximab Beta) by EUSA Pharma for patients with High Risk Neuroblastoma in LATAM and APAC regions
agosto 20, 2018
FarmaMondo to manage access to Asparaginase (Spectrila® by Medac Pharma) for patients with acute lymphoblastic leukemia in Russia and CIS region
marzo 15, 2018
FarmaMondo appointed by Amomed Pharma to exclusively Manage Access for Argipressin (Empressin®) for Russia and CIS region
enero 1, 2018
FarmaMondo establishes presence in south EU markets to provide direct to hospital service around supply of unlicensed medicines
noviembre 1, 2017
FarmaMondo establishes presence in Mexico to provide direct to hospital service around supply of unlicensed medicines
octubre 17, 2017
FarmaMondo to manage access to Dinutuximab beta EUSA for patients with Neuroblastoma
octubre 17, 2017
FarmaMondo to manage access to Qarziba® (Dinutuximab Beta) by EUSA Pharma) for patients with High Risk Neuroblastoma in Russia and CIS region
agosto 15, 2013